Orexigen Shares Plummet Following FDA Decision; Competition Gets A Bump
Orexigen Therapeutics (NASDAQ: OREX) on Tuesday announced that the FDA has issued a three-month extension for the review of Orexigen's new weight-loss drug, NB32.
The FDA report indicated the reason for the extension was to reach an agreement on the post-marketing obligation of cardiovascular outcomes.
Orexigen CEO Michael Narachi commented, "We are encouraged by the high level of engagement with the FDA, and are confident that we can reach agreement on the remaining post-marketing obligation."
Following the pre-market announcement, shares of Orexigen have fallen as much as 17 percent and were trading around the $5.62 mark, at last check.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.